Application of Proteomics in Sarcoidosis

• Published in: American journal of respiratory cell and molecular biology Vol. 63; no. 6; pp. 727 - 738
• Main Authors: Guerrero, Candance R., Maier, Lisa A., Griffin, Timothy J., Higgins, LeeAnn, Najt, Charles P., Perlman, David M., Bhargava, Maneesh
• Format: Journal Article
• Language: English
• Published: United States American Thoracic Society 01.12.2020
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Alveoli; Bioinformatics; Blood cells; Ceruloplasmin; Clathrin; Complement component C3; Cystatins; Data acquisition; Data processing; Endocytosis; Exosomes; Humans; Hypoxia; Lung - metabolism; Lung diseases; Lung Diseases, Interstitial - metabolism; Macrophages; Macrophages, Alveolar - metabolism; MAP kinase; Mass spectrometry; Mass spectroscopy; Phagocytosis; Pluripotency; Proteins; Proteins - metabolism; Proteomics; Proteomics - methods; Protocadherin; Sarcoidosis; Sarcoidosis, Pulmonary - metabolism; TOR protein; sarcoidosis; proteomics; biomarkers; pulmonary sarcoidosis
• ISSN: 1044-1549; 1535-4989; 1535-4989
• DOI: 10.1165/rcmb.2020-0070PS

Sarcoidosis is a multisystem disease with heterogeneity in manifestations and outcomes. System-level studies leveraging "omics" technologies are expected to define mechanisms contributing to sarcoidosis heterogeneous manifestations and course. With improvements in mass spectrometry (MS) and bioinformatics, it is possible to study protein abundance for a large number of proteins simultaneously. Contemporary fast-scanning MS enables the acquisition of spectral data for deep coverage of the proteins with data-dependent or data-independent acquisition MS modes. Studies leveraging MS-based proteomics in sarcoidosis have characterized BAL fluid (BALF), alveolar macrophages, plasma, and exosomes. These studies identified several differentially expressed proteins, including protocadherin-2 precursor, annexin A2, pulmonary surfactant A2, complement factors C3, vitamin-D-binding protein, cystatin B, and amyloid P, comparing subjects with sarcoidosis with control subjects. Other studies identified ceruloplasmin, complement factors B, C3, and 1, and others with differential abundance in sarcoidosis compared with other interstitial lung diseases. Using quantitative proteomics, most recent studies found differences in PI3K/Akt/mTOR, MAP kinase, pluripotency-associated transcriptional factor, and hypoxia response pathways. Other studies identified increased clathrin-mediated endocytosis and Fcγ receptor-mediated phagocytosis pathways in sarcoidosis alveolar macrophages. Although studies in mixed BAL and blood cells or plasma are limited, some of the changes in lung compartment are detected in the blood cells and plasma. We review proteomics for sarcoidosis with a focus on the existing MS data acquisition strategies, bioinformatics for spectral data analysis to infer protein identity and quantity, unique aspects about biospecimen collection and processing for lung-related proteomics, and proteomics studies conducted to date in sarcoidosis.